文献速递脑血管病

应用估计目标框架管理COVID-19对卒中临床试验的干扰效应

Use of the Estimand Framework to Manage the Disruptive Effects of COVID-19 on Stroke Clinical Trials.
PubMed 文献 · Stroke · 2021-09-30

本文介绍国际人用药品注册技术协调会(ICH)的估计目标框架,聚焦其在卒中临床试验中的应用。框架旨在将试验的临床与科学目标同设计及终点对齐,并前瞻性考虑随机化后可能发生的伴发事件(如COVID-19疫情)。文中描述了伴发事件的分类及应对策略,并给出脑出血和卒中恢复领域假设性试验的实施示例。

要点

  • 估计目标框架帮助卒中试验在设计阶段明确临床问题与终点的对应关系。
  • COVID-19疫情作为伴发事件来源,需前瞻性识别并制定应对策略以保护试验完整性。
  • 该框架与原则同样适用于卒中领域其他可能影响临床试验的事件或问题。

核心结论

  • ICH估计目标框架可用于管理COVID-19疫情对卒中临床试验的干扰,并保护试验完整性。

研究设计与样本

  • 文中以脑出血和卒中恢复领域的假设性试验为例,展示估计目标框架的实施。

主要发现

  • 估计目标框架旨在将试验的临床与科学目标同其设计和终点对齐。
  • 框架鼓励前瞻性考虑随机化后可能发生的伴发事件,这些事件可能影响终点的测量或解释。
  • 文中描述了伴发事件的不同类别及拟议的应对策略,并聚焦COVID-19疫情作为伴发事件来源。

临床怎么用

  • 研究者应仔细审查COVID-19疫情对试验、卫生系统、研究组和参与者的潜在实际影响。
  • 应确保具备适当的实践和统计策略,以保护试验完整性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The coronavirus disease 2019 (COVID-19) pandemic has presented unique challenges to stroke care and research internationally. In particular, clinical trials in stroke are vulnerable to the impacts of the pandemic at multiple stages, including design, recruitment, intervention, follow-up, and interpretation of outcomes. A carefully considered approach is required to ensure the appropriate conduct of stroke trials during the pandemic and to maintain patient and participant safety. This has been recently addressed by the International Council for Harmonisation which, in November 2019, released an addendum to the Statistical Principles for Clinical Trials guidelines entitled Estimands and Sensitivity Analysis in Clinical Trials. In this article, we present the International Council for Harmonisation estimand framework for the design and conduct of clinical trials, with a specific focus on its application to stroke clinical trials. This framework aims to align the clinical and scientific objectives of a trial with its design and end points. It also encourages the prospective consideration of potential postrandomization intercurrent events which may occur during a trial and either impact the ability to measure an end point or its interpretation. We describe the different categories of such events and the proposed strategies for dealing with them, specifically focusing on the COVID-19 pandemic as a source of intercurrent events. We also describe potential practical impacts posed by the COVID-19 pandemic on trials, health systems, study groups, and participants, all of which should be carefully reviewed by investigators to ensure an adequate practical and statistical strategy is in place to protect trial integrity. We provide examples of the implementation of the estimand framework within hypothetical stroke trials in intracerebral hemorrhage and stroke recovery. While the focus of this article is on COVID-19 impacts, the strategies and principles proposed are well suited for other potential events or issues, which may impact clinical trials in the field of stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yassi N, Hayward KS, Campbell BCV, et al. Use of the Estimand Framework to Manage the Disruptive Effects of COVID-19 on Stroke Clinical Trials. Stroke. 2021. PMID: 34587797. doi:10.1161/STROKEAHA.121.036537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。